ESC Premium Access

Roundtable discussion: the future of SGLT2i CVOT trials: do we need more data? What are we hoping to learn.

Congress Presentation

About the speakers

Professor Lawrence Leiter

University of Toronto, Toronto (Canada)
19 presentations
0 follower

Doctor Anselm Kai Gitt

Klinikum Ludwigshafen, Ludwigshafen (Germany)
15 presentations
0 follower

3 more presentations in this session

Opening Remarks - The future of SGLT2 Inhibitor Cardiovascular Outcomes trials: what are we hoping to learn?

Speaker: Professor L. Leiter (Toronto, CA) Doctor A. Gitt (Ludwigshafen, DE)

Thumbnail

SGLT2i Trials: current synopsis.

Speaker: Doctor A. Gitt (Ludwigshafen, DE)

Thumbnail

Closing remarks - The future of SGLT2 Inhibitor Cardiovascular Outcomes trials: what are we hoping to learn?

Speaker: Professor L. Leiter (Toronto, CA) Doctor A. Gitt (Ludwigshafen, DE)

Thumbnail

Access the full session

The future of SGLT2 Inhibitor Cardiovascular Outcomes trials: what are we hoping to learn?

Speakers: Professor L. Leiter, Doctor A. Gitt, Professor L. Leiter, Doctor A. Gitt, Doctor A. Gitt...
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb